Actelion selects IntraLinks for clinical trial data exchange

Published: 26-Sep-2012
Regulatory Digital

Streamlines documentation process while improving efficiency and security


Swiss biopharmaceutical firm Actelion Pharmaceuticals has selected IntraLinks’ Connect system to streamline its documentation exchange during clinical trials.

Allschwil/Basel-based Actelion focuses on the discovery, development, and commercialisation of medicines to serve unmet medical needs.

IntraLinks is a global technology provider of content management and collaboration solutions.

Actelion had previously relied on traditional courier services to move sensitive clinical trial documentation between sponsors and participants, resulting in excessive shipping costs and manual processes for tracking and other activities.

To streamline the documentation process and improve efficiency and security, Actelion will use IntraLinks Connect to provide central clinical trial portals to facilitate auditable exchange of site feasibility, study start up, study conduct and study close-out documentation.

IntraLinks Connect's security, detailed reporting, workflows, and analytics, plus the firm’s service support convinced Actelion that IntraLinks provided the best fit for its requirements.

Christine Schwenninger, head of Global Clinical Monitoring at Actelion, said: ‘While working with IntraLinks we can see the maturity of their technology and the commitment of the team to support Actelion moving forward in this area.

‘We are looking forward to working closely together with IntraLinks in the coming years.’

Andy Watson, vp of life sciences EMEA at IntraLinks, added: ‘Actelion's engagement of IntraLinks demonstrates the growing demand for secure information exchange within the clinical trial process.’

‘IntraLinks’ Connect will provide Actelion with greater efficiency, traceability, and security to improve communication, collaboration, and document exchange between everyone involved in the clinical trial.’

  • Companies:
  • Actelion
  • IntraLinks
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

Read more
As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  3. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  4. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  5. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Clinical trials and the Cloud

Document exchange and collaboration has been a laborious process, with couriers physically transporting documents to and from locations. Such an approach has serious security implications and puts confidential data at risk if documents are lost. Even fax and e-mail have shortcomings, which is why Cloud computing, or hosted services delivered over the Internet, looks an attractive alternative
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Analysis

IMPACT CKD model reveals the escalating toll of chronic kidney disease

The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Subscribe now